{"id":46889,"date":"2022-08-03T16:01:57","date_gmt":"2022-08-03T14:01:57","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/immunabs-inc-announces-us-fda-approval-for-a-phase-1-clinical-trial\/"},"modified":"2022-08-03T16:01:57","modified_gmt":"2022-08-03T14:01:57","slug":"immunabs-inc-announces-us-fda-approval-for-a-phase-1-clinical-trial","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/immunabs-inc-announces-us-fda-approval-for-a-phase-1-clinical-trial\/","title":{"rendered":"ImmunAbs Inc. Announces US FDA Approval for a Phase 1 Clinical Trial"},"content":{"rendered":"
\n

SEOUL, South Korea–(BUSINESS WIRE)–ImmunAbs Inc. (www.immunabs.com<\/a>) announced that it has received US FDA approval for a Phase 1 clinical trial and that it is now ready to initiate a phase 1 clinical trial in the United States.\n<\/p>\n

<\/a><\/p>\n

\nImmunAbs is developing IM-101, a monoclonal antibody targeting complements that play essential roles in the immune system but, when out of regulation, cause various autoimmune diseases, including but not limited to paroxysmal nocturnal hemoglobinuria (PNH). The complement inhibitors drug market showed its growth potential by achieving an average annual growth rate of 20.7% and a market size of USD $ 5.1 billion in 2020 and is expected to grow to USD $19 billion by 2027.\n<\/p>\n

\nParoxysmal nocturnal hemoglobinuria is one example of complement-mediated autoimmune diseases where the membrane proteins protecting the red blood cells from complement activation are lost due to mutations, which results in red blood cells being destructed by the complements. Due to insufficient inhibition of complements shown by currently approved complement inhibitors, Soliris\u24c7<\/sup> and Ultomiris\u24c7<\/sup>, patients who receive these drugs still suffer from the residual symptoms of PNH, which include anaemia, fatigue, and decreased productivity at work.\n<\/p>\n

\nImmunAbs\u2019 new complement therapeutic IM-101 targets the safest and most potent component of the complement system, complement C5. IM-101 has been shown to completely inhibit complement activation, and thus is expected to alleviate the symptoms that persist with the standard of care. ImmunAbs will initiate a phase 2a clinical trial in the United States in 2024.\n<\/p>\n

\n\u201cThis is a historical milestone for ImmunAbs.\u201d said Dr. DongJo Kim, the company\u2019s CEO. \u201cWe are delighted to see IM-101\u2019s efficacy in humans which has been proven in our ex vivo<\/i> study. We hope that our IM-101 will reach patients who may suffer from symptoms that persist due to insufficient complement inhibition by the current treatments.\u201d\n<\/p>\n

\nAbout ImmunAbs Inc.\n<\/p>\n

\nImmunAbs Inc. was established in 2017 by experts of global standard antibody therapeutics development. The vision is “Hope for Patients, Dreams for All.” Currently, ImmunAbs has several antibody therapeutics in global standard development for autoimmune diseases, diabetic retinopathy, and metabolic syndrome. ImmunAbs successfully raised KRW 18.1 billion from Seed to series A funding in 2021 and got a non-clinical study national grant for developing IM-101 from Korea Drug Development Fund in November last year.\n<\/p>\n

Contacts<\/b> <\/p>\n

\nHyunJung Jung
\n
Business Development Manager
\n
Hyunjung.Jung@ImmunAbs.com<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

SEOUL, South Korea–(BUSINESS WIRE)–ImmunAbs Inc. (www.immunabs.com) announced that it has received US FDA approval for a Phase 1 clinical trial and that it is now ready to initiate a phase 1 clinical trial in the United States. ImmunAbs is developing IM-101, a monoclonal antibody targeting complements that play essential roles in the immune system but, … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-46889","6":"format-standard","7":"category-industry"},"yoast_head":"\nImmunAbs Inc. Announces US FDA Approval for a Phase 1 Clinical Trial - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/immunabs-inc-announces-us-fda-approval-for-a-phase-1-clinical-trial\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"ImmunAbs Inc. Announces US FDA Approval for a Phase 1 Clinical Trial - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"SEOUL, South Korea–(BUSINESS WIRE)–ImmunAbs Inc. (www.immunabs.com) announced that it has received US FDA approval for a Phase 1 clinical trial and that it is now ready to initiate a phase 1 clinical trial in the United States. ImmunAbs is developing IM-101, a monoclonal antibody targeting complements that play essential roles in the immune system but, ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/immunabs-inc-announces-us-fda-approval-for-a-phase-1-clinical-trial\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-08-03T14:01:57+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20220803005380\/en\/1533298\/21\/immunabs_logo_e1.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/immunabs-inc-announces-us-fda-approval-for-a-phase-1-clinical-trial\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/immunabs-inc-announces-us-fda-approval-for-a-phase-1-clinical-trial\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"ImmunAbs Inc. Announces US FDA Approval for a Phase 1 Clinical Trial\",\"datePublished\":\"2022-08-03T14:01:57+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/immunabs-inc-announces-us-fda-approval-for-a-phase-1-clinical-trial\\\/\"},\"wordCount\":391,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/immunabs-inc-announces-us-fda-approval-for-a-phase-1-clinical-trial\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220803005380\\\/en\\\/1533298\\\/21\\\/immunabs_logo_e1.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/immunabs-inc-announces-us-fda-approval-for-a-phase-1-clinical-trial\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/immunabs-inc-announces-us-fda-approval-for-a-phase-1-clinical-trial\\\/\",\"name\":\"ImmunAbs Inc. Announces US FDA Approval for a Phase 1 Clinical Trial - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/immunabs-inc-announces-us-fda-approval-for-a-phase-1-clinical-trial\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/immunabs-inc-announces-us-fda-approval-for-a-phase-1-clinical-trial\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220803005380\\\/en\\\/1533298\\\/21\\\/immunabs_logo_e1.jpg\",\"datePublished\":\"2022-08-03T14:01:57+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/immunabs-inc-announces-us-fda-approval-for-a-phase-1-clinical-trial\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/immunabs-inc-announces-us-fda-approval-for-a-phase-1-clinical-trial\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/immunabs-inc-announces-us-fda-approval-for-a-phase-1-clinical-trial\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220803005380\\\/en\\\/1533298\\\/21\\\/immunabs_logo_e1.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220803005380\\\/en\\\/1533298\\\/21\\\/immunabs_logo_e1.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/immunabs-inc-announces-us-fda-approval-for-a-phase-1-clinical-trial\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"ImmunAbs Inc. Announces US FDA Approval for a Phase 1 Clinical Trial\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"ImmunAbs Inc. Announces US FDA Approval for a Phase 1 Clinical Trial - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/immunabs-inc-announces-us-fda-approval-for-a-phase-1-clinical-trial\/","og_locale":"en_US","og_type":"article","og_title":"ImmunAbs Inc. Announces US FDA Approval for a Phase 1 Clinical Trial - Pharma Trend","og_description":"SEOUL, South Korea–(BUSINESS WIRE)–ImmunAbs Inc. (www.immunabs.com) announced that it has received US FDA approval for a Phase 1 clinical trial and that it is now ready to initiate a phase 1 clinical trial in the United States. ImmunAbs is developing IM-101, a monoclonal antibody targeting complements that play essential roles in the immune system but, ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/immunabs-inc-announces-us-fda-approval-for-a-phase-1-clinical-trial\/","og_site_name":"Pharma Trend","article_published_time":"2022-08-03T14:01:57+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20220803005380\/en\/1533298\/21\/immunabs_logo_e1.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/immunabs-inc-announces-us-fda-approval-for-a-phase-1-clinical-trial\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/immunabs-inc-announces-us-fda-approval-for-a-phase-1-clinical-trial\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"ImmunAbs Inc. Announces US FDA Approval for a Phase 1 Clinical Trial","datePublished":"2022-08-03T14:01:57+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/immunabs-inc-announces-us-fda-approval-for-a-phase-1-clinical-trial\/"},"wordCount":391,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/immunabs-inc-announces-us-fda-approval-for-a-phase-1-clinical-trial\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220803005380\/en\/1533298\/21\/immunabs_logo_e1.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/immunabs-inc-announces-us-fda-approval-for-a-phase-1-clinical-trial\/","url":"https:\/\/pharma-trend.com\/en\/immunabs-inc-announces-us-fda-approval-for-a-phase-1-clinical-trial\/","name":"ImmunAbs Inc. Announces US FDA Approval for a Phase 1 Clinical Trial - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/immunabs-inc-announces-us-fda-approval-for-a-phase-1-clinical-trial\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/immunabs-inc-announces-us-fda-approval-for-a-phase-1-clinical-trial\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220803005380\/en\/1533298\/21\/immunabs_logo_e1.jpg","datePublished":"2022-08-03T14:01:57+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/immunabs-inc-announces-us-fda-approval-for-a-phase-1-clinical-trial\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/immunabs-inc-announces-us-fda-approval-for-a-phase-1-clinical-trial\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/immunabs-inc-announces-us-fda-approval-for-a-phase-1-clinical-trial\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20220803005380\/en\/1533298\/21\/immunabs_logo_e1.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20220803005380\/en\/1533298\/21\/immunabs_logo_e1.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/immunabs-inc-announces-us-fda-approval-for-a-phase-1-clinical-trial\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"ImmunAbs Inc. Announces US FDA Approval for a Phase 1 Clinical Trial"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/46889","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=46889"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/46889\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=46889"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=46889"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=46889"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}